- Price
- $2.24
- Day
- +2.75%
- Mkt Cap
- $161.79M
- 52W Range
- $1.19 – $3.60
- Volume
- 283.4K
- Beta
- 0.34
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
Read full article
NEWTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced new findings presented at the Alzheimer's Association International Conference (AAIC®) 2026 in London. Following collaboration with JCR Pharmaceuticals Co., Ltd. (JCR) on EBD candidate development, studies demonstrated improved brain penetration of anti-AβO antibodies through transferrin receptor-mediated delivery across both mouse and non-human primate models. Additionally, research from early symptomatic AD patients highlighted the lived experience among ALTITUDE-AD trial participants and their study partners.
Read full article
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
Read full article
Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read full article